BNB PLUS CORP (BNBX)
NASDAQFinancialsBiotechnologySnapshot 2026-09-04
$0.14-12.50%
Close 2026-08-10 · 1-day change
NASDAQFinancialsBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Maintain Nasdaq listing by meeting $1.00 bid price requirement: 0.14 USD vs 1.00 USD.
BNB Plus Corp is raising capital through private placements, securing $2.5 million in Q2 2026. The company aims to meet Nasdaq's $1.00 bid price to maintain listing. These steps support financial stability and regulatory compliance. If successful, they could stabilize the business and improve prospects.
The company is loss-making with negative free cash flow yield of -4.05%. Revenue is expected to decline about 38% next year. Recent equity sales dilute shareholders and signal financial stress. The stock has fallen 44% from its high, showing weak market confidence.
The market expects about -38% revenue decline and stretched negative growth over 3-5 years. Our fair value near $1.37 reflects this weak outlook. The price already discounts a difficult turnaround with high risk.
Breaks if: capital raised falls below $2.5 million in 2026-Q2
Breaks if: share price remains below $1.00 for extended period risking delisting
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in a volatile environment. The company is currently facing operational challenges and is loss-making, with a medium confidence level in its recovery potential.
The market seems to have priced in a low expectations gap compared to peers, indicating that BNBX is viewed as relatively cheap. However, the overall valuation reflects concerns about its ongoing losses and weak recent performance.
Fundamentals may remain under pressure in the near term due to a high probability of an earnings miss. Recent financial performance has been weak, with significant revenue declines, suggesting that management's strategic priorities are still in early stages.
The long-term thesis hinges on the outcomes of management's strategic review and the company's ability to address Nasdaq listing compliance. Additionally, the performance of sector bellwethers like JPM, BAC, and GS will be crucial for BNBX's momentum.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Respond to Nasdaq delisting determination and seek review to maintain listing or manage transition to OTCQB market.
Newly stated in 2026-Q3. The company received a Nasdaq delisting determination in July 2026 due to failure to meet the $1.00 bid price requirement and plans to seek review. Trading was suspended on Nasdaq and transitioned to OTCQB. This regulatory priority is recent and reflects compliance challenges; financials show ongoing losses and no reversal of the delisting event.
Breaks if: revenue decline exceeds -38% in FY26
Overall, BNBX is in a precarious position with mixed signals from management and high near-term risks. Not investment advice.